Search Quotes, News, Mutual Fund NAVs

Upgrade 🙆 Hello, Login



🕈 Omicron Markets 🗸 News 🗸 Portfolio Commodities Mutual Funds 🗸 Personal Finance 🗸 Forum 🗸 Media 🗸 Earth360 Invest Now 🗸 Subscription 🗸 📴 PRO

Business Markets Stocks Economy Companies Trends IPO Opinion

Live Now |Markets League Dec'21 Edition - 4 Days Live Hedge Trading Virtual Conference brought to you by Moneycontrol Pro →

Home > News > Business > STOCKS

Dr Reddy's, Strides Pharma shares rally on DCGI approval for COVID-19 drug

Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2

MONEYCONTROL NEWS





Dr Reddy's Laboratories and Strides Pharma Science share price jumped 1-2 percent intraday on December 29 after both the companies received approval from the Drugs Controller General of India (DCGI) to launch Molnupiravir in India.

"<u>Strides Pharma Science</u> has received emergency use authorization from the Drugs Controller General of India (DCGI) to launch Molnupiravir 200mg in India," company said in its release.

Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2 and the clinical studies have shown this drug to be active against the most common COVID-19 variants, it added.

Catch all the market action on our live blog

"**Dr. Reddy's Laboratories** also received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug Molnupiravir capsules 200mg for the 🗆 🖂 🖨 A+



These stocks turned wealth destroyers in 2021; What should investors expect in 2022?

WATCH MORE

MUST LISTEN



Simply Save | How 2021 affected your personal finances

STAY UPDATED



YOU MIGHT ALSO LIKE



4 Worst Diabetes Medicines vibranthealthnetwork



Your IQ Is Over 140 If You Get Even 5/20 On This Quiz Parentsdome Galleries



treatment of adult patients with COVID-19, with SpO2 >93% and who have high risk of progression of the disease including hospitalisation or death," it said in a press release.

RELATED STORIES



Nifty, Bank Nifty adjustment to come into effect on Friday; Reliance, IndusInd Bank to see highest i…



ICICI Securities retains 'buy' on UltraTech Cement which is set to be debt-free by H1FY23 -- here's ...



G R Infraprojects share price jumps 3% on emerging lowest bidder for Noida Metro project

Earlier this year, Dr. Reddy's entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).

A meeting of board of directors of Dr. Reddy's Laboratories will be held on January 28, 2022, to consider and approve the unaudited financial results of the company for the quarter and nine months ending on December 31, 2021.

At 09:46 hrs Dr Reddy's

Laboratories was quoting at Rs 4,806, up Rs 62.60, or 1.32 percent and Strides Pharma Science was quoting at Rs 459.15, up Rs 5.85, or 1.29 percent on the BSE.

MONEYCONTROL NEWS

TAGS: #Buzzing Stocks #Dr Reddys Laboratories #Strides Pharma Science FIRST PUBLISHED: DEC 29, 2021 10:13 AM

Dr Reddy's, Strides Pharma shares rally on DCGI approval for...


RBI says OCIs don't need its approval for acquisition or transfer of...

Simply Save | How 2021 affected your personal finances

Money Grants Now Available That You Don't Have to Pay Back Money Grants | Search Ads



[Gallery] Linda Evans Turns 75 & Is **Definitely Not Like We Remembered** DailyChoices



About us | Contact Us | Advertise with Us | Support | Disclaimer | Privacy Policy | Cookie Policy | Terms & Conditions | Careers | Financial Terms (Glossary) | FAQs | Sitemap | RSS Feed

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.

Dr Reddy's, Strides Pharma shares rally on DCGI approval for... RBI says OCIs don't need its approval for acquisition or transfer of...

Simply Save | How 2021 affected your personal finances

>